AQST analyst estimates
Aquestive Therapeutics (AQST) analyst ratings, the average price target and its range, and every firm's latest call.
AQST analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 16, 2026 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Aquestive Therapeutics (AQST) | $10.00 |
| Sep 10, 2026 | Cantor Fitzgerald | Cantor Fitzgerald Reiterates Overweight Rating on Aquestive Therapeutics (AQST) | $11.00 |
| Feb 3, 2026 | Lake Street | Aquestive Therapeutics price target lowered to $6 from $8 at Lake Street | $6.00 |
| Feb 2, 2026 | New Street | Alliance Global sees Aquestive's Anaphylm CRL as fixable, reiterates Buy rating | $12.00 |
| Oct 9, 2025 | JMP Securities | Aquestive Therapeutics price target raised to $12 from $9 at Citizens JMP | $12.00 |
| Mar 7, 2025 | Raymond James | Aquestive Therapeutics price target lowered to $7 from $8 at Raymond James | $7.00 |
| Nov 6, 2024 | Loop Capital Markets | Aquestive Therapeutics (AQST) PT Raised to $10 at Lake Street Capital Markets | $10.00 |
| Jun 25, 2024 | Loop Capital Markets | Aquestive Therapeutics (AQST) PT Lowered to $7 at Lake Street Capital Markets | $7.00 |
| Apr 11, 2024 | Piper Sandler | Piper Sandler Starts Aquestive Therapeutics (AQST) at Overweight, 'he risk/reward profile associated with AQST shares is attractive' | $10.00 |
| Mar 18, 2024 | H.C. Wainwright | Aquestive Therapeutics (AQST) PT Raised to $9 at H.C. Wainwright | $9.00 |
| Mar 15, 2024 | Oppenheimer | Aquestive Therapeutics (AQST) PT Raised to $12 at Oppenheimer | $12.00 |
- 2 firms rate AQST: 2 buy, 0 hold, 0 sell.
- The average price target is $10.50 from 2 analysts, from $10.00 to $11.00.
Updated 2026-11-05 12:48 UTC